Interleukin-2: all 213 studies that test it
Page 1 of 3. Open to participants first (32), then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)RecruitingNCT07830342Phase 1
- Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum DisorderNot yet recruitingNCT07809724Phase 2
- Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseRecruitingNCT07651319Phase 1/2
- Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T CellsRecruitingNCT07610538Not applicable
- Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsRecruitingNCT07443020Phase 1
- TIL Therapy in cSCC and MCCRecruitingNCT07288073Phase 2
- A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PCRecruitingNCT07255664Phase 1/2
- Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseRecruitingNCT07192900Phase 1
- HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)RecruitingNCT07105176Phase 1
- Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV ViremiaNot yet recruitingNCT06971913Phase 2
- Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological TumorsRecruitingNCT06584006Phase 2
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian CancerRecruitingNCT06321484Phase 1
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingNCT06138587Phase 1
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT06121570Phase 1
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT06121557Phase 1
- Phase II Clinical Trial of Interleukin-2 in ADRecruitingNCT06096090Phase 2
- Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid TumorsRecruitingNCT06047977Phase 1
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT05981014Phase 1/2
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT05981001Phase 1/2
- Venetoclax Combined With Azactidine in the Treatment of ALALRecruitingNCT05901974Phase 2
- Efficacy of Interleukin-2 in Triple Negative Breast CancerNot yet recruitingNCT05821686Phase 1/2
- Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic CancerNot yet recruitingNCT05810792Phase 2
- Quadruple Immunotherapy for NeuroblastomaRecruitingNCT05754684Phase 2
- TIL Cells for the Treatment of the Advanced Solid Tumors PatientsNot yet recruitingNCT05649618Early Phase 1
- TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid TumorsNot yet recruitingNCT05648994Early Phase 1
- The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LNRecruitingNCT05631717Phase 3
- PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.Not yet recruitingNCT05530200Phase 2
- Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus ErythematosusRecruitingNCT05339217Phase 3
- Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid TumorsRecruitingNCT05141474Early Phase 1
- A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.RecruitingNCT04166006Phase 2
- Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid TumorsRecruitingNCT03891706Phase 1
- Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.RecruitingNCT02919644Phase 2
- Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue SarcomaCompletedNCT04052334Phase 1Results posted
- Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid TumorsTerminatedNCT03991741Phase 1Results posted
- High Dose IL-2 in Combination With Anti-PD-1TerminatedNCT03991130Phase 2Results posted
- Anti-PD-1 Antibody With HD IL-2 in Metastatic MelanomaTerminatedNCT03476174Phase 2Results posted
- UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeActive, not recruitingNCT03474497Phase 1/2Results posted
- HIV Reservoir Reduction With Interleukin-2TerminatedNCT03308786Phase 2Results posted
- Ph1 T-Regulatory Cells in Amyotrophic Lateral SclerosisCompletedNCT03241784Phase 1Results posted
- Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell CancerCompletedNCT02989714Phase 1/2Results posted
- Interleukin-2 and Pembrolizumab for Metastatic Kidney CancerCompletedNCT02964078Phase 2Results posted
- Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant RecipientsCompletedNCT02739412Phase 2Results posted
- Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid ArthritisCompletedNCT02467504Phase 2Results posted
- A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHDCompletedNCT02340676Phase 2Results posted
- Low-dose IL-2( Interleukin-2) Treatment in SLECompletedNCT02084238Not applicableResults posted
- In Vivo Treg Expansion and Graft-Versus-Host Disease ProphylaxisCompletedNCT01927120Phase 2Results posted
- Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT01898793Phase 1/2Results posted
- High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal CancerCompletedNCT01896271Phase 2Results posted
- Therapy for Children With Advanced Stage NeuroblastomaCompletedNCT01857934Phase 2Results posted
- HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaTerminatedNCT01856023Phase 4Results posted
- Interleukin-2 in Metastatic Kidney CancerTerminatedNCT01702909Phase 2Results posted
- Interleukin-2 in Metastatic MelanomaTerminatedNCT01702896Phase 2Results posted
- Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsCompletedNCT01701674Not applicableResults posted
- Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic MelanomaCompletedNCT01659151Phase 2Results posted
- Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)CompletedNCT01550367Phase 1/2Results posted
- T-Cell Depleted Double UCB for Refractory AMLTerminatedNCT01464359Phase 2Results posted
- In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and SirolimusTerminatedNCT01453140Phase 1/2Results posted
- Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-DiseaseActive, not recruitingNCT01366092Phase 2Results posted
- Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous LeukemiaTerminatedNCT01289678Phase 2Results posted
- High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCICompletedNCT01266603Phase 2Results posted
- High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With MelanomaCompletedNCT01124734Phase 2Results posted
- Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast CancerCompletedNCT01105650Phase 2Results posted
- Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic MelanomaCompletedNCT01005745Not applicableResults posted
- Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's LymphomaCompletedNCT00994643Phase 2Results posted
- Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) PatientsTerminatedNCT00913913Phase 2Results posted
- Study of Gene Modified Immune Cells in Patients With Advanced MelanomaCompletedNCT00910650Phase 2Results posted
- Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney CancerTerminatedNCT00582790Phase 2Results posted
- Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHDCompletedNCT00539695Phase 2Results posted
- Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host DiseaseCompletedNCT00529035Phase 1Results posted
- Biochemotherapy With Temozolomide for Metastatic MelanomaTerminatedNCT00505635Phase 2Results posted
- Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast CancerTerminatedNCT00376805Phase 2Results posted
- Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney CancerCompletedNCT00328861Phase 2Results posted
- Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic MelanomaCompletedNCT00314106Phase 2Results posted
- Natural Killer (NK) Cell Transplantation for AMLCompletedNCT00187096Not applicableResults posted
- Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected PeopleCompletedNCT00110812Phase 2Results posted
- Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell LymphomaCompletedNCT00101101Phase 2Results posted
- Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral TxCompletedNCT00071890Phase 2Results posted
- Peptide Vaccination for Patients at High Risk for Recurrent MelanomaCompletedNCT00059475Phase 2Results posted
- An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral TherapyCompletedNCT00004978Phase 3Results posted
- Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic MelanomaCompletedNCT00001832Phase 2Results posted
- Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled StudyCompletedNCT06884670Phase 2
- Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial CarcinomaActive, not recruitingNCT06318871Early Phase 1
- Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic MelanomaCompletedNCT06151847Phase 2
- Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical TrailCompletedNCT06108596Phase 2
- The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.Active, not recruitingNCT05975554Not applicable
- Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory MelanomaCompletedNCT05628883Phase 1
- Low-dose Interleukin-2 and Rapamycin on sjögren's SyndromeCompletedNCT05605665Phase 1/2
- Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)Status unknownNCT05603013Phase 2
- Interleukin-2 on Active DermatomyositisStatus unknownNCT05495321Phase 3
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedNCT05400122Phase 1
- Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus ErythematosusStatus unknownNCT05262686Phase 3
- Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With LeiomyosarcomaCompletedNCT05080790Phase 2
- Low Dose IL-2 in the Treatment of Immune-associated ALS SyndromeStatus unknownNCT04952155Phase 2
- Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous UrticariaStatus unknownNCT04893980Phase 2/3
- Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)Status unknownNCT04892498Phase 2
- A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2Status unknownNCT04766307Phase 4
- The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic DiseasesCompletedNCT04397107Not applicable
- The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein PurpuraCompletedNCT04387942Not applicable
- Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORYCompletedNCT04241601Phase 2
- Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory MyopathyStatus unknownNCT04237987Phase 2